Ragsdale Alexandra S, Al-Hammadi Noor, Loux Travis M, Bass Sabel, Keller Justine M, Chavan Niraj R
Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology and Women's Health, Saint Louis University/SSM Health, St Louis, MO, USA.
Department of Health and Clinical Outcomes Research, Advanced HEAlth Data Research Institute, Saint Louis University, St Louis, MO, USA.
Eur J Obstet Gynecol Reprod Biol X. 2024 Apr 21;22:100308. doi: 10.1016/j.eurox.2024.100308. eCollection 2024 Jun.
Substance use disorder is a growing concern in the USA, especially among pregnant women. This study was undertaken to assess the impact of substance use disorder on adverse pregnancy outcomes using a nationwide sample of inpatient pregnancy hospitalizations in the USA, and to elucidate the influence on each type of adverse pregnancy outcome.
A cross-sectional analysis of inpatient pregnancy hospitalizations in the USA from the Healthcare Cost and Utilization Project National Inpatient Sample from 2016 to 2020 was conducted. International Classification of Diseases - 10th revision and diagnosis-related group codes were used to identify inpatient pregnancy-related delivery hospitalizations with a substance use disorder and/or adverse pregnancy outcomes. Propensity score matching and multiple logistic regression analyses were undertaken to predict the likelihood of adverse pregnancy outcomes among pregnancy hospitalizations with and without substance use disorder. Subgroup analyses were performed to estimate the impact of substance use disorder on each adverse pregnancy outcome.
From 3,238,558 hospitalizations, the prevalence of adverse pregnancy outcomes was substantially higher among pregnancy hospitalizations with substance use disorder (35.6 %) compared with pregnancy hospitalizations without substance use disorder (25.1 %, < 0.001). After matching and model adjustment for sociodemographic covariates, substance use disorder was identified as an independent predictor of adverse pregnancy outcomes [adjusted odds ratio (aOR) 1.47, 95 % confidence interval (CI) 1.45-1.49]. In subgroup analyses based on type of adverse pregnancy outcome, the greatest exposure risks were fetal growth restriction (aOR 1.96, 95 % CI 1.91-2.01), antepartum hemorrhage (aOR 1.79, 95 % CI 1.73-1.85) and preterm birth (aOR 1.65, 95 % CI 1.62-1.68).
Patients with substance use disorder are at higher risk of adverse pregnancy outcomes, particularly fetal growth restriction, antepartum hemorrhage and preterm birth.
物质使用障碍在美国日益引起关注,尤其是在孕妇中。本研究旨在利用美国住院妊娠的全国样本评估物质使用障碍对不良妊娠结局的影响,并阐明其对每种不良妊娠结局的影响。
对2016年至2020年医疗成本和利用项目全国住院样本中美国住院妊娠进行横断面分析。使用国际疾病分类第十版和诊断相关组代码来识别患有物质使用障碍和/或不良妊娠结局的与住院妊娠相关的分娩住院病例。采用倾向得分匹配和多元逻辑回归分析来预测有无物质使用障碍的妊娠住院病例中不良妊娠结局的可能性。进行亚组分析以估计物质使用障碍对每种不良妊娠结局的影响。
在3238558例住院病例中,患有物质使用障碍的妊娠住院病例的不良妊娠结局患病率(35.6%)显著高于无物质使用障碍的妊娠住院病例(25.1%,P<0.001)。在对社会人口统计学协变量进行匹配和模型调整后,物质使用障碍被确定为不良妊娠结局的独立预测因素[调整后的优势比(aOR)为1.47,95%置信区间(CI)为1.45-1.49]。在基于不良妊娠结局类型的亚组分析中,最大的暴露风险是胎儿生长受限(aOR为1.96,95%CI为1.91-2.01)、产前出血(aOR为1.79,95%CI为1.73-1.85)和早产(aOR为1.65,95%CI为1.62-1.68)。
患有物质使用障碍的患者发生不良妊娠结局的风险更高,尤其是胎儿生长受限、产前出血和早产。